Skip to main navigation Toggle Main Menu Side Menu INVESTORS AND NEWS Seres' news, events and other information can be found throughout the pages below. Investor Relations STOCK INFORMATION NEWS AND EVENTS FINANCIAL INFORMATION CORPORATE GOVERNANCE SHAREHOLDER SERVICES CORPORATE PROFILE Seres Therapeutics is a late-clinical-stage biotechnology company with a strong development pipeline and rigorous scientific underpinning, working to revolutionize treatment of a wide range of diseases by modulating the function of the human microbiome. READ MORE RECENT NEWS Nov 30, 2021 Seres Therapeutics Announces First Patient Enrolled in Phase 1b Study of SER-155, an Investigational Microbiome Therapeutic to Reduce the Risk of Antibiotic-Resistant Bacterial Infections and Graft-Versus-Host Disease (GvHD) Nov 24, 2021 Seres Therapeutics to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference Nov 10, 2021 Seres Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates LNK NEWS READ MORE RECENT EVENTS Seres Therapeutics, Inc. at the Piper Sandler 33rd Annual Virtual Healthcare Conference Nov 22, 2021 at 7:00 AM EST Click Here for Webcast Q3 2021 Seres Therapeutics, Inc. Earnings Conference Call Nov 10, 2021 at 8:30 AM EST Click Here for Webcast RECENT PRESENTATION Corporate Presentation LNK EVENTS READ MORE NASDAQ GS: MCRB $10.68 Change-0.75 (-6.56%) Volume2,526,710 52 Week High$29.90 52 Week Low$5.41 Dec 3, 2021 4:00 PM EST Data Provided by Refinitiv. Minimum 15 minutes delayed. Shareholder Tools RSS FEEDS E-MAIL ALERTS PRINT © 2021 Seres Therapeutics. Footer Left Menu Privacy Policy Terms of Use Follow us on Linkedin Follow us on Twitter Follow us on Facebook